Sec. 20-579. (Formerly Sec. 20-175). Causes for suspension, revocation or refusal to issue or renew licenses, temporary permits and registrations and for assessment of civil penalty. (a) The commission may refuse to authorize the issuance of a
temporary permit to practice pharmacy, may refuse to authorize the issuance or renewal
of a license to practice pharmacy, a license to operate a pharmacy or a registration of a
pharmacy intern or pharmacy technician, and may revoke or suspend a license or temporary permit to practice pharmacy, a license to operate a pharmacy, or a registration of
a pharmacy intern or a pharmacy technician, and may assess a civil penalty of up to one
thousand dollars or take other action permitted in subdivision (7) of section 21a-7 if the
applicant or holder of the license, temporary permit or registration: (1) Has violated a
statute or regulation relating to drugs, devices or the practice of pharmacy of this state,
any state of the United States, the United States, the District of Columbia, the Commonwealth of Puerto Rico, any territory or insular possession subject to the jurisdiction of
the United States or a foreign jurisdiction; (2) has been convicted of violating any criminal statute relating to drugs, devices or the practice of pharmacy of this state, any state
of the United States, the United States, the District of Columbia, the Commonwealth
of Puerto Rico, any territory or insular possession subject to the jurisdiction of the United
States or a foreign jurisdiction; (3) has been disciplined by, or is the subject of pending
disciplinary action or an unresolved complaint before, the duly authorized pharmacy
disciplinary agency of any state of the United States, the United States, the District of
Columbia, the Commonwealth of Puerto Rico, any territory or insular possession subject
to the jurisdiction of the United States or a foreign jurisdiction; (4) has been refused a
license or registration or renewal of a license or registration by any state of the United
States, the United States, the District of Columbia, the Commonwealth of Puerto Rico,
any territory or insular possession subject to the jurisdiction of the United States or a
foreign jurisdiction based on grounds that are similar to grounds on which Connecticut
could refuse to issue or renew such a license or registration; (5) has illegally possessed,
diverted, sold or dispensed drugs or devices; (6) abuses or excessively uses drugs, including alcohol; (7) has made false, misleading or deceptive representations to the public
or the commission; (8) has maintained exclusive telephone lines to, has maintained
exclusive electronic communication with, or has exclusive access to computers located
in offices of prescribing practitioners, nursing homes, clinics, hospitals or other health
care facilities; (9) has substituted drugs or devices except as permitted in section 20-619; (10) has accepted, for return to regular stock, any drug already dispensed in good
faith or delivered from a pharmacy, and exposed to possible and uncontrolled contamination or substitution; (11) has split fees for professional services, including a discount or
rebate, with a prescribing practitioner or an administrator or owner of a nursing home,
hospital or other health care facility; (12) has entered into an agreement with a prescribing practitioner or an administrator or owner of a nursing home, hospital or other health
care facility for the compounding or dispensing of secret formula or coded prescriptions;
(13) has performed or been a party to a fraudulent or deceitful practice or transaction; (14)
has presented to the commission a diploma, license or certificate illegally or fraudulently
obtained, or obtained from a college or school of pharmacy not approved by the commission; (15) has performed incompetent or negligent work; (16) has falsified a continuing
education document submitted to the commission or department or a certificate retained
in accordance with the provisions of subsection (d) of section 20-600; (17) has permitted
a person not licensed to practice pharmacy in this state to practice pharmacy in violation
of section 20-605, to use a pharmacist license or pharmacy display document in violation
of section 20-608, or to use words, displays or symbols in violation of section 20-609;
or (18) has failed to maintain the entire pharmacy premises, its components and contents
in a clean, orderly and sanitary condition.
(b) The commission may refuse to authorize the issuance of a temporary permit to
practice pharmacy, may refuse to authorize the issuance or renewal of a license to practice pharmacy, a license to operate a pharmacy or a registration of a pharmacy intern
or pharmacy technician, and may revoke or suspend a license or temporary permit to
practice pharmacy, a license to operate a pharmacy, or a registration of a pharmacy
intern or a pharmacy technician, or take other action permitted in subdivision (7) of
section 21a-7 if the commission determines that the applicant or holder of the license,
temporary permit or registration has a condition including, but not limited to, physical
illness or loss of skill or deterioration due to the aging process, emotional disorder or
mental illness, abuse or excessive use of drugs or alcohol that would interfere with the
practice of pharmacy, operation of a pharmacy or activities as a pharmacy intern or
pharmacy technician, provided the commission may not, in taking action against a license, temporary permit or registration holder on the basis of such a condition, violate
the provisions of section 46a-73 or 42 USC Section 12132 of the federal Americans
with Disabilities Act.
(1949 Rev., S. 4472; 1961, P.A. 149; 1963, P.A. 243; February, 1965, P.A. 162; 304, S. 2; 1969, P.A. 74; P.A. 73-480,
S. 3, 4; P.A. 75-95, S. 2, 3; P.A. 76-166, S. 5, 8; P.A. 77-126, S. 1, 2; 77-614, S. 203, 610; P.A. 82-419, S. 42, 47; P.A.
84-75; P.A. 87-401, S. 3, 4; P.A. 95-264, S. 10; P.A. 98-31, S. 4; P.A. 99-175, S. 14; P.A. 00-182, S. 7.)
History: 1961 act changed technical language, required conviction in Subdiv. (1), added refusal to comply in Subdiv.
(3) and added Subdivs. (4) to (16); 1963 act added Subdiv. (17); 1965 acts added Subdiv. (18) and amended Subdiv. (3)
by adding "chapter 343 or"; 1969 act added Subdiv. (19) allowing revocation or suspension of license for failure to maintain
sanitary conditions; P.A. 73-480 revised Subdiv. (17) to ban advertising or promotion of legend drugs rather than of those
bearing cautionary label and made ban more forceful by adding "directly or indirectly, by any means, in any form"; P.A.
75-95 deleted former Subdiv. (17) banning advertising and renumbered remaining Subdivs.; P.A. 76-166 revised Subdiv.
(8) banning drug substitution except as provided in Secs. 20-185b and 20-185c rather than "except on the order of a
practitioner legally licensed to prescribe such articles"; P.A. 77-126 deleted Subdiv. (17) banning use on words "discount"
or "cut rate" etc. in promotion or advertisement of services, renumbering Subdiv. (18) accordingly; P.A. 77-614 transferred
power to make regulations from commission to consumer protection commissioner, retaining commission as advisor,
effective January 1, 1979; P.A. 82-419 amended section to eliminate crimes involving moral turpitude, lack of professional
integrity, advertising professional superiority and unprofessional conduct as disciplinary grounds and to change grounds
of unfitness, incompetence, unskillfulness or gross negligence to performance of grossly incompetent or negligent work;
P.A. 84-75 added as a cause for the revocation or suspension of a license access to computers located in offices of practitioners, nursing homes or clinics; P.A. 87-401 made falsification of certificate of approved continuing education units
grounds for suspension or revocation of license; P.A. 95-264 replaced existing section with new provisions permitting the
suspension, revocation and refusal to issue or renew licenses and registrations; Sec. 20-175 transferred to Sec. 20-579 in
1997; P.A. 98-31 added provisions re pharmacy technicians and made technical changes; P.A. 99-175 made technical
changes and amended Subsec. (a) to empower commission to assess one thousand dollar civil penalty against persons who
violate pharmacy license or registration statutes, rules or regulations; P.A. 00-182 added provisions re temporary permit
to practice pharmacy.
See Sec. 19a-70 re violation of regulations governing distribution of biologic products during an emergency as grounds
for suspension, revocation or annulment of license.
See Sec. 30-36 re druggist's permit to sell alcoholic beverages.
Sec. 20-580. (Formerly Sec. 20-167). Revocation or suspension of nonlegend
drug permit. A permit to sell nonlegend drugs issued under section 20-624 may be
revoked or suspended by the commission for any violation of the provisions of chapter
419 or of sections 20-570 to 20-630, inclusive, or for any violation of any federal law
concerning the sale or offer for sale of any nonlegend drug, or for the violation of any
regulation concerning the sale or offer for sale of any nonlegend drugs.
(1949 Rev., S. 4466; 1959, P.A. 270; February, 1965, P.A. 304, S. 1; P.A. 77-614, S. 200, 610; P.A. 95-264, S. 11;
P.A. 99-175, S. 15.)
History: 1959 act applied commission's authority to make regulations to sale or offer for sale of compounds, etc. rather
than to the grant of a selling permit to an unlicensed pharmacy, specified above provision's application to proprietary or
patent medicinal compounds be in the alternative and extended conditions under which permit may be revoked or suspended
from violation of commission's regulations to those stated in second sentence; 1965 act added reference to chapter 343;
P.A. 77-614 transferred power to make regulations from commission of pharmacy to commissioner of consumer protection,
retaining commission as advisor and replaced permittee's right to appeal with right to judicial review, effective January 1,
1979; P.A. 95-264 deleted provisions concerning adoption of regulations re proprietary or patent medicines and substituted
provisions re revocation or suspension of nonlegend drug permits; Sec. 20-167 transferred to Sec. 20-580 in 1997; P.A.
99-175 made a technical change and replaced reference to Sec. 20-625 with reference to Sec. 20-630.
Sec. 20-581. (Formerly Sec. 20-185). Penalty for violation of Pharmacy Practice Act. Exception. Any person who violates any provision of sections 20-570 to 20-630, inclusive, for the violation of which no other penalty has been provided shall be
fined not more than five thousand dollars or imprisoned not more than five years or
both. For purposes of this section, each instance of patient contact or consultation that
is in violation of any provision of sections 20-570 to 20-630, inclusive, shall be a separate
offense. Failure to renew in a timely manner any license issued under said sections is
not a violation for purposes of this section.
(1949 Rev., S. 4486; P.A. 84-526, S. 12; P.A. 95-264, S. 12; P.A. 99-175, S. 16.)
History: P.A. 84-526 amended section by changing penalty for violation of any provision of Secs. 20-163 to 20-184c,
inclusive, to a fine of not more than five hundred dollars or imprisonment of not more than five years, and added provisions
that each instance of patient contact or consultation shall constitute a separate offense and failure to renew license in timely
manner is not a violation for purposes of section; P.A. 95-264 increased maximum fine from five hundred to five thousand
dollars for violations of the Pharmacy Practice Act, excluding failure to renew license in a timely manner; Sec. 20-185
transferred to Sec. 20-581 in 1997; P.A. 99-175 made technical changes and replaced references to Sec. 20-625 with
references to Sec. 20-630.
Sec. 20-582. (Formerly Sec. 20-176). Appeals of decisions of Commission of
Pharmacy. Any person (1) holding a license, permit or registration under sections 20-570 to 20-630, inclusive, who has been disciplined by the commission, or (2) who has
been refused a license, permit or registration under said sections or refused a renewal
of a license or permit under said sections, may appeal as provided in section 4-183.
(1949 Rev., S. 4473; 1971, P.A. 179, S. 13; 870, S. 61; P.A. 76-436, S. 425, 681; P.A. 77-603, S. 71, 125; 77-614, S.
204, 610; P.A. 78-280, S. 41, 42, 127; P.A. 95-264, S. 13; P.A. 99-175, S. 17.)
History: 1971 acts required that appeals be taken between twelve and thirty days after service rather than on next return
day or the "next but one" and replaced superior court with court of common pleas, effective September 1, 1971, except
that courts with cases pending retain jurisdiction unless pending matters deemed transferable; P.A. 76-436 replaced court
of common pleas with superior court and added references to judicial districts, effective July 1, 1978; P.A. 77-603 replaced
appeal provisions, except those concerning venue and privileged status with statement that appeals be in accordance with
Sec. 4-183; P.A. 77-614 deleted provisions concerning venue and privileged status of appeals, effective January 1, 1979;
P.A. 78-280 restored venue provision and provision granting appeals privileged status; P.A. 95-264 deleted provisions on
where appeals are returnable; Sec. 20-176 transferred to Sec. 20-582 in 1997; P.A. 99-175 added Subdiv. indicators and
added references to Secs. 20-570 to 20-630, inclusive.
Annotation to former section 20-176:
Cited. 179 C. 415, 424.
Sec. 20-583. Where appeals returnable. An appeal of a decision by the commission to discipline a person licensed to practice pharmacy or registered as a pharmacy
intern or pharmacy technician, to refuse a person's application for a license to practice
pharmacy or to refuse to register a person as a pharmacy intern or pharmacy technician
shall be made returnable to the judicial district in which the person resides or, if the
person does not reside in Connecticut, to the judicial district of New Britain. An appeal
of a decision by the commission to discipline the holder of a pharmacy license or the
holder of a permit to sell nonlegend drugs or to refuse a person's application for such
a license or permit appeal shall be made returnable to the judicial district in which the
building or store is located, for which the license or permit was sought or in which it
was suspended or revoked. All appeals under the provisions of this section shall be
treated as privileged and shall be assigned for trial and tried as soon as may be practicable.
(P.A. 88-230, S. 1, 12; P.A. 90-98, S. 1, 2; P.A. 93-142, S. 4, 7, 8; P.A. 95-220, S. 4-6; 95-264, S. 14; P.A. 98-31, S.
5; P.A. 99-215, S. 24, 29.)
History: (Revisor's note: P.A. 88-230, 90-98, 93-142 and 95-220 authorized substitution of "judicial district of Hartford"
for "judicial district of Hartford-New Britain" in 1995 public and special acts, effective September 1, 1998); P.A. 98-31
added provisions re pharmacy technicians; P.A. 99-215 replaced "judicial district of Hartford" with "judicial district of
New Britain", effective June 29, 1999.
Secs. 20-584 to 20-589. Reserved for future use.
PART II
LICENSING OF PHARMACISTS AND PHARMACIES.
REGISTRATION OF PHARMACY INTERNS
AND PHARMACY TECHNICIANS
Sec. 20-590. (Formerly Sec. 20-170). Issuance of license or temporary permit
to practice pharmacy; requirements. (a) The department shall, upon authorization of
the commission, issue a license to practice pharmacy as a pharmacist to any individual
provided the individual:
(1) Has submitted a written application on a form approved by the department;
(2) Has graduated from a college or school of pharmacy approved by the commission with a degree that was, at the time of graduation, an entry level professional pharmacy degree;
(3) Has the professional experience as a pharmacy intern required by regulations
adopted by the commissioner, with the advice and assistance of the commission, in
accordance with chapter 54;
(4) Has successfully passed the examination described under subsection (b) of this
section;
(5) Is eighteen years of age or older at the time of the examination; and
(6) Has paid the examination fee specified in section 20-601.
(b) The examination for licensure required under subsection (a) of this section shall
be given by the commission at least two times each year. The commission shall, with
the approval of the commissioner, determine the content and subject matter of each
examination, and the place, time and date of administration of the examination.
(c) The Department of Consumer Protection shall, upon authorization of the commission, issue a temporary permit to practice pharmacy to an individual who: (1) Practices under the direct supervision of a licensed pharmacist; (2) has an application for
reciprocity on file with the commission; (3) is a licensed pharmacist in good standing
in a state or jurisdiction from which such state's pharmacy board or commission of
pharmacy grants similar reciprocal privileges to pharmacists licensed in this state; and
(4) has no actions pending against such individual's license with any state's pharmacy
board or commission of pharmacy.
(d) A temporary permit to practice pharmacy shall expire at the time the individual
with the temporary permit is licensed as a pharmacist in this state, or not later than three
months from the date of issuance of such temporary permit, whichever occurs first. The
Department of Consumer Protection shall not issue more than one temporary permit to
practice pharmacy to an individual, but the commission, at its discretion, may authorize
one three-month extension of the temporary permit.
(1949 Rev., S. 4469; 1963, P.A. 197, S. 1; 1972, P.A. 127, S. 41; P.A. 76-113, S. 7; P.A. 77-614, S. 202, 610; P.A. 81-361, S. 3, 39; 81-471, S. 69, 71; P.A. 86-392, S. 2, 3; May Sp. Sess. P.A. 92-6, S. 25, 117; P.A. 93-79; P.A. 94-36, S. 7,
42; P.A. 95-264, S. 15; P.A. 99-175, S. 18; P.A. 00-182, S. 8; P.A. 02-82, S. 2; June 30 Sp. Sess. P.A. 03-6, S. 146(d);
P.A. 04-169, S. 17; 04-189, S. 1.)
History: 1963 act established license year from April first to March thirty-first; 1972 act reduced minimum age of
applicant from twenty-one to eighteen, reflecting changed age of majority; P.A. 76-113 deleted requirement that applicant
be U.S. citizen; P.A. 77-614 required approval of exam by consumer protection commissioner and replaced regulation
"prescribed by ... commission" with regulations "established under this chapter", effective January 1, 1979; P.A. 81-361
amended section to allow the department rather than commission itself to issue licenses upon the authorization of the
commission on and after July 1, 1981, and to require approval of application forms by the department instead of the
commission; P.A. 81-471 amended section to establish procedure under which pharmacist licensed in another state and
who was eligible for licensure in this state prior to October 22, 1976, by reason of his licensure in such other state may be
licensed in this state by examination without regard to accreditation or nonaccreditation of the school of pharmacy which
he attended; P.A. 86-392 changed the requirements for licensure for persons who are licensed pharmacists in another state
to allow licensure for persons graduating after October 22, 1976, who have practiced for at least five years and to refer to
alternative examination in addition to national boards; May Sp. Sess. P.A. 92-6 established an examination fee of one
hundred fifty dollars; P.A. 93-79 required the commissioner of consumer protection to adopt regulations concerning the
licensure of graduates of foreign schools of pharmacy (Revisor's note: In 1995 the term "pharmacy commission" was
changed editorially by the Revisors to "commission of pharmacy", where appearing, for consistency with Sec. 20-163);
P.A. 94-36 deleted reference to "April first to March thirty-first" license year, effective January 1, 1995; P.A. 95-264
replaced existing provisions re qualifications for license with new provisions setting out the requirements which must be
met; Sec. 20-170 transferred to Sec. 20-590 in 1997; P.A. 99-175 made technical changes and amended Subdiv. (3) of
Subsec. (a) to add provision requiring commissioner to seek advice and assistance of commission in adopting regulations
re professional qualifications of pharmacy interns; P.A. 00-182 added Subsec. (c) re issuance of a temporary permit to
practice pharmacy and Subsec. (d) re expiration and extension of a temporary permit to practice pharmacy; P.A. 02-82
amended Subsec. (a)(2) to require, as condition of issuance of license to practice pharmacy, a degree from an approved
college or school of pharmacy and that the degree, at time of individual's graduation, was an "entry level professional
pharmacy degree"; June 30 Sp. Sess. P.A. 03-6 and P.A. 04-169 replaced Department of Consumer Protection with Department of Agriculture and Consumer Protection, effective July 1, 2004; P.A. 04-189 repealed Sec. 146 of June 30 Sp. Sess.
P.A. 03-6, thereby reversing the merger of the Departments of Agriculture and Consumer Protection, effective June 1, 2004.
See Sec. 21a-10(b) re staggered schedule for license renewals.
Sec. 20-591. Graduates of foreign pharmacy schools. Regulations. (a) An individual who has graduated from a foreign school of pharmacy not approved by the commission may apply for a license to practice pharmacy under this section.
(b) The individual shall comply with the requirements of subdivisions (1), (2), (4),
(5) and (6) of subsection (a) of section 20-590 and with regulations adopted as provided
in subsection (c) of this section.
(c) The commissioner shall, with the advice and assistance of the commission, adopt
regulations in accordance with chapter 54 concerning licensure as a pharmacist of an
individual who has graduated from and received an entry-level professional pharmacy
degree from a foreign school of pharmacy. The regulations shall include a requirement
that such a graduate pass a proficiency test for written and spoken English, a foreign
pharmacy graduate equivalency examination and the examination described in subsection (b) of section 20-590.
(P.A. 95-264, S. 16; P.A. 99-175, S. 19.)
History: P.A. 99-175 made a technical change in Subsec. (a).
Sec. 20-592. Licensure of individual who is a licensed pharmacist in another
state or jurisdiction. Any individual who is a licensed pharmacist in any other state of
the United States, the District of Columbia, the Commonwealth of Puerto Rico or any
territory or insular possession subject to the jurisdiction of the United States, may be
licensed to practice pharmacy in this state in accordance with regulations adopted under
sections 20-570 to 20-630, inclusive, in accordance with chapter 54.
(P.A. 95-264, S. 17; P.A. 99-175, S. 20.)
History: P.A. 99-175 amended Subsec. (a) to delete subsection designation and reference to Subsec. (b) and replace
reference to Sec. 20-625 with reference to Sec. 20-630 and deleted Subsec. (b).
Sec. 20-593. (Formerly Sec. 20-172). Pharmacist license certificate; expiration; renewal; fee; display document. (a) A license to practice pharmacy issued under
the provisions of section 20-590 or under the provisions of section 20-591 or 20-592
and a license to practice pharmacy renewed pursuant to subsections (b) and (c) of this
section shall be evidenced by a certificate issued by the department upon authorization
of the commission.
(b) A license to practice pharmacy shall expire annually and may be renewed upon
completion of an application on a form approved by the department, payment of the fee
set forth in section 20-601 and completion of continuing professional education, as
required by sections 20-599 and 20-600.
(c) The commission shall not grant a renewal license to an applicant who has not
held a license authorized by the commission within five years of the date of application
unless the applicant has passed an examination satisfactory to the commission and has
paid the fee required in section 20-601.
(d) In addition to the certificate of license to practice pharmacy issued under subsection (a) of this section, the department may issue a document suitable for display indicating that the individual has been issued a certificate of license to practice pharmacy.
(1949 Rev., S. 4471; 1959, P.A. 616, S. 55; June, 1971, P.A. 8, S. 62; 1972, P.A. 223, S. 9; P.A. 79-224, S. 3; P.A. 81-361, S. 5, 39; P.A. 89-251, S. 99, 203; May Sp. Sess. P.A. 92-16, S. 49, 89; P.A. 94-36, S. 8, 42; P.A. 95-264, S. 18; P.A.
99-175, S. 21.)
History: 1959 act increased license fees for pharmacists from fifteen to twenty-five dollars, renewal fees from two to
five dollars and doubled fees for pharmacists licensed in another state admitted to practice in this state; 1971 act increased
fees for pharmacists and pharmacists licensed in another state from twenty-five and fifty dollars respectively to one hundred
fifty dollars for both, for renewal from five to one hundred dollars and for renewal not within six months of expiration
from ten to one hundred twenty-five dollars; 1972 act reduced pharmacists' fees to fifty dollars and annual renewal to
fifteen dollars; P.A. 79-224 required payment of fees to state treasurer rather than commission treasurer and introduced
intermediate renewal penalty of fifty dollars for failure to renew within thirty days of expiration; P.A. 81-361 amended
section to provide that certificates of licensure are to be issued by the department instead of the commission and that
application fees are nonrefundable; P.A. 89-251 increased fee for a pharmacist's license from fifty dollars to one hundred
dollars, increased fee for renewal from fifteen dollars to thirty dollars and increased fee for licensure from another jurisdiction from fifty dollars to one hundred dollars; May Sp. Sess. P.A. 92-16 replaced thirty-dollar renewal fee with professional
service fee class established pursuant to Sec. 33-182l; (Revisor's note: In 1995 the term "pharmacy commission" was
changed editorially by the Revisors to "commission of pharmacy" for consistency with Sec. 20-163); P.A. 94-36 deleted
provision allowing license renewal late fees, effective January 1, 1995; P.A. 95-264 replaced existing provisions re licensure
with new provisions concerning license certificates, their expiration, renewal and fee and the issuance of a display document
by the department; Sec. 20-172 transferred to Sec. 20-593 in 1997; P.A. 99-175 made technical changes in Subsecs. (a)
and (d).
See Sec. 21a-4(c) re fines for late license renewals.
Sec. 20-594. (Formerly Sec. 20-168). Pharmacy license; application; information required; issuance or renewal of license; expiration. Transfer of pharmacy to
new location. (a) Except as limited by section 20-596, a pharmacist or any other person
may apply to the commission for a pharmacy license or for renewal of a pharmacy
license.
(b) The applicant shall disclose on the application the name and address of the
applicant and the owner of the pharmacy, the name and street and mailing address of
the pharmacy and the name, address and license number of the pharmacist who manages
the pharmacy. The commissioner may, by regulation adopted with the advice and assistance of the commission, in accordance with chapter 54, require such other information
on the application as is necessary for the department to carry out its duties under sections
20-570 to 20-630, inclusive.
(c) The department shall, after receipt of an application under this section, (1) issue,
on authorization of the commission, a pharmacy license to an applicant for a new pharmacy on payment of the fee required in section 20-601 and on satisfactory evidence to
the commission that the pharmacy will be managed by a pharmacist and will be operated
in accordance with the general statutes and the regulations adopted by the commissioner
in accordance with chapter 54, and (2) issue a renewal of a pharmacy license to an
applicant on payment of the fee required in section 20-601.
(d) Pharmacy licenses shall expire annually. Pharmacy licenses may be renewed
on application and payment of the fee required in section 20-601 for a period not to
exceed one year.
(e) When a pharmacy is transferred to a new location the pharmacy license for
such pharmacy shall terminate. A pharmacy license that has been terminated under this
subsection may be renewed under the provisions of subsection (d) of this section and
on satisfactory evidence to the commission that the pharmacy will be managed by a
pharmacist and will be operated in accordance with the general statutes and the regulations adopted by the commissioner in accordance with chapter 54.
(1949 Rev., S. 4467; 1959, P.A. 616, S. 54; 1967, P.A. 109, S. 4; June, 1971, P.A. 8, S. 61; 1972, P.A. 223, S. 8; P.A.
77-614, S. 201, 610; P.A. 81-361, S. 1, 39; P.A. 89-251, S. 96, 203; P.A. 94-36, S. 6, 42; P.A. 95-264, S. 19; P.A. 99-175,
S. 22.)
History: 1959 act raised fee for renewal from ten to fifteen dollars; 1967 act added "or dentists" to first sentence; 1971
act raised fee for renewal license from fifteen to one hundred fifty dollars; 1972 act reduced renewal fee to fifty dollars; P.A.
77-614 replaced regulations of commission with regulations established by consumer protection commissioner, effective
January 1, 1979; P.A. 81-361 transferred licensing power from commission to department of consumer protection acting
upon commission's authorization; P.A. 89-251 increased the licensing fee from two hundred dollars to six hundred dollars
and increased the renewal fee from fifty dollars to one hundred fifty dollars; P.A. 94-36 deleted reference to "September
first" license expiration date, effective January 1, 1995; P.A. 95-264 replaced existing provisions re pharmacy licenses
with new provisions concerning application for license or renewal of license, information required, issuance or renewal
of license, expiration and transfer of pharmacy to new location; Sec. 20-168 transferred to Sec. 20-594 in 1997; P.A. 99-175 made technical changes and amended Subsecs. (c) and (e) to require that adoption of regulations be consistent with
chapter 54.
See Sec. 21a-10(b) re staggered schedule for license renewals.
Sec. 20-595. (Formerly Sec. 20-168a). Pharmacy licenses held by corporations.
Notice of change in officers or directors. Any corporation applying for a new or renewal pharmacy license under the provisions of section 20-594 shall state in the application the names of the officers and directors of the corporation. Notice of any change in
such officers or directors shall be given by the corporation to the commission within
ten days after the change. Such notice shall be accompanied by the filing fee set forth
in section 20-601. Any such corporation that fails to give notice of a change in the
officers or directors of the corporation within ten days of the change shall pay the late
fee required in section 20-601.
(February, 1965, P.A. 421; P.A. 79-224, S. 1; P.A. 89-251, S. 97, 203; P.A. 95-264, S. 20; P.A. 99-175, S. 23.)
History: P.A. 79-224 imposed twenty-five-dollar fine for failure to give notice of change in officers or directors or to
apply for renewal upon change in location or name; P.A. 89-251 increased fee for notice of change from ten dollars to
thirty dollars; P.A. 95-264 replaced specific filing and late fees with references to fees set forth in Sec. 20-601; Sec. 20-168a transferred to Sec. 20-595 in 1997; P.A. 99-175 made technical changes.
Sec. 20-596. (Formerly Sec. 20-168b). Ownership of pharmacies by prescribing practitioners. (a) No prescribing practitioner, spouse of a prescribing practitioner,
except a spouse who is a pharmacist, or dependent child of a prescribing practitioner
shall have an ownership or investment interest in a pharmacy.
(b) The provisions of this section do not apply to a prescribing practitioner or spouse
or dependent child of a prescribing practitioner (1) having an ownership or investment
interest in a pharmacy prior to July 1, 1993, (2) who inherits an ownership or investment
interest in a pharmacy, or (3) who is not required to maintain professional liability
insurance pursuant to section 20-11b, provided (A) if the prescribing practitioner reinstates any such professional liability insurance, the prescribing practitioner shall, within
thirty days of doing so, notify the Commissioner of Public Health of such reinstatement
and divest any interest the prescribing practitioner may have in any pharmacy, or (B)
if the interest is owned by the prescribing practitioner's spouse or dependent child, the
spouse or child shall divest such interest in any pharmacy. Failure of the prescribing
practitioner or the prescribing practitioner's spouse or dependent child to divest any
such interest in a pharmacy within thirty days shall result in the prescribing practitioner's
license being suspended until such time as the prescribing practitioner or the prescribing
practitioner's spouse or dependent child divests such interest in the pharmacy.
(c) As used in this section, "ownership of investment interest" does not include
ownership of investment securities by a prescribing practitioner, or the prescribing practitioner's spouse or dependent children, in a publicly-held corporation that is traded on
a national exchange or over-the-counter market, provided the investment securities held
by the prescribing practitioner, the prescribing practitioner's spouse and the prescribing
practitioner's dependent children, in the aggregate, do not exceed one-half of one per
cent of the total number of shares issued by the corporation.
(P.A. 93-374, S. 1, 2; P.A. 95-257, S. 12, 21, 58; 95-264, S. 21; 95-271, S. 32; P.A. 99-175, S. 24.)
History: P.A. 93-374 effective July 1, 1993; P.A. 95-257 replaced Commissioner and Department of Public Health and
Addiction Services with Commissioner and Department of Public Health, effective July 1, 1995; P.A. 95-264 substituted
"prescribing practitioner" for "licensed practitioner"; P.A. 95-271 added Subdiv. (3) of Subsec. (b) re exemption for certain
individuals required to maintain professional liability insurance under Sec. 20-11b and that failure to divest within thirty
days can result in suspension (Revisor's note: A reference to "licensed" practitioner was replaced editorially by the Revisors
with "prescribing" practitioner to conform P.A. 95-271 with changes enacted in P.A. 95-264); Sec. 20-168b transferred
to Sec. 20-596 in 1997; P.A. 99-175 made technical and gender neutral changes.
Sec. 20-597. (Formerly Sec. 20-169). Pharmacy to be supervised and managed
by pharmacist. Regulations re prescription department. Change in management,
ownership or name of pharmacy. (a) No place of business may be operated as a pharmacy unless a pharmacy license has been issued for the place of business and unless it
is under the direct supervision of a pharmacist on the premises, except that the commissioner, with the advice and assistance of the commission, shall adopt regulations, in
accordance with chapter 54, that specify when a pharmacy may remain open for business
during hours when a pharmacist is not present and directly supervising such pharmacy.
Such regulations shall include, but not be limited to: (1) A provision requiring that the
prescription department be closed and properly secured during times when a pharmacist
is not present; (2) the minimum number of hours of operation applicable to the prescription department; (3) requirements for the physical security of the prescription department; (4) requirements for the physical security of legend drugs, controlled substances
and legend devices stored in all areas of the pharmacy; and (5) a definition of the term
"prescription department".
(b) In addition to the on-premises supervision of a pharmacy required in subsection
(a) of this section, a pharmacy shall be managed by a pharmacist practicing at the pharmacy on a full-time basis who is listed as manager in the application for a pharmacy
license made under section 20-594 or enrolled with the commission under subsection
(c) of this section. The managing pharmacist may also act as the supervising pharmacist.
No pharmacist may manage more than one pharmacy at the same time.
(c) The person to whom a pharmacy license has been issued shall immediately
notify the commission whenever the pharmacist who manages the pharmacy ceases
such management and shall immediately enroll with the commission the name, address
and license number of the pharmacist who assumes management of the pharmacy. The
notice of change in management of a pharmacy required to be filed with the commission
under this section shall be accompanied by the filing fee required in section 20-601.
The pharmacist who ceases management of the pharmacy shall also immediately notify
the commission of that fact.
(d) The person to whom a pharmacy license has been issued shall immediately
notify the commission of a change in ownership of the pharmacy and of a change in
name of the pharmacy. The notice shall be accompanied by the filing fee required in
section 20-601. Any such person who fails to give the notice of a change in ownership
or name of the pharmacy within ten days of the change shall pay the late fee required
in section 20-601.
(1949 Rev., S. 4468; 1971, P.A. 385, S. 2; P.A. 79-224, S. 2; P.A. 89-251, S. 98, 203; P.A. 95-72, S. 3; 95-264, S. 22;
P.A. 98-211, S. 1; P.A. 99-175, S. 25.)
History: 1971 act rephrased provision re operation of pharmacy by licensed pharmacist and added provisions requiring
certain information to be reported to pharmacy commission by owner of pharmacy, pharmacist ceasing to be in charge of
pharmacy, etc.; P.A. 79-224 imposed twenty-five-dollar fine for failure to give notice of change in officers or directors or
failure to apply for renewal upon change in location or name; P.A. 89-251 established a forty-five-dollar fee for notice of
change; (Revisor's note: In 1995 the term "pharmacy commission" was changed editorially by the Revisors to "commission
of pharmacy" for consistency with Sec. 20-163); P.A. 95-72 required commissioner to adopt regulations specifying when
a pharmacy may remain open when the pharmacist is not present, deleting prior provision which had permitted assistant
pharmacists to assume charge of pharmacy during pharmacist's temporary absence, but failed to take effect, P.A. 95-264
having taken precedence; P.A. 95-264 replaced existing provisions re supervision and management of pharmacy and
change in ownership of pharmacy with new provisions concerning supervision and management of pharmacies, notification
of Commission of Pharmacy when there is a change of management or change in ownership or name of pharmacy and
payment of fees; Sec. 20-169 transferred to Sec. 20-597 in 1997; P.A. 98-211 amended Subsec. (a) by adding provisions
re prescription department regulations; P.A. 99-175 amended Subsec. (c) to make technical changes.
Sec. 20-598. (Formerly Sec. 20-177). Registration of pharmacy interns. (a)
Each individual who is employed by or is serving under the supervision of a pharmacist
in a pharmacy or institutional pharmacy for the purpose of obtaining the professional
experience required under the provisions of section 20-590 shall register as a pharmacy
intern with the commission at the time of commencing employment or service under
such supervision. The applicant may not be registered as a pharmacy intern unless the
applicant has successfully completed two years of college and is enrolled in a professional program at a school or college of pharmacy, accredited by the American Council
on Pharmaceutical Education and approved by the commission, or has completed the
requirements for graduation from such a school or college, or, if the applicant is a graduate from a foreign pharmacy school not approved by the commission, has passed a
proficiency test for written and spoken English and a foreign pharmacy graduate equivalency examination. The application for registration shall be certified to, under oath, by
the applicant.
(b) The fee required in section 20-601 shall accompany an application for registration and an identification number and card shall be issued by the commission to the
applicant. The identification number and card shall become void and shall be returned
to the commission if the pharmacy intern does not complete the requirements for graduation from, or terminates enrollment at, an accredited and approved school or college of
pharmacy.
(1949 Rev., S. 4474; 1959, P.A. 616, S. 56; June, 1971, P.A. 8, S. 63; P.A. 82-70, S. 1, 2; P.A. 89-251, S. 100, 203;
P.A. 95-264, S. 23; P.A. 99-175, S. 26.)
History: 1959 act increased fee from fifty cents to five dollars; 1971 act increased fee to ten dollars; P.A. 82-70 required
that pharmacy interns successfully complete two years of college and be enrolled in an accredited program or graduate
from such college and be employed in a pharmacy before beginning the internship; and eliminated all references to an
apprenticeship; P.A. 89-251 increased the registration fee from ten dollars to thirty dollars; P.A. 95-264 replaced provisions
on registration of pharmacy interns with new provisions concerning the registration of pharmacy interns; Sec. 20-177
transferred to Sec. 20-598 in 1997; P.A. 99-175 made technical changes.
Sec. 20-598a. Registration and certification of pharmacy technicians. (a) No
person shall act as a pharmacy technician unless registered with, or certified with, the
department.
(b) The department shall, upon authorization of the commission, register as a pharmacy technician any person who presents evidence satisfactory to the department that
such person is qualified to perform, under the direct supervision of a pharmacist, routine
functions in the dispensing of drugs that do not require the use of professional judgment.
The qualifications for registration as a pharmacy technician under this section shall be
in accordance with (1) the standards of an institutional pharmacy, a care-giving institution or a correctional or juvenile training institution, in the case of employment in any
such pharmacy or institution, or (2) the standards established by regulation adopted by
the commissioner in accordance with chapter 54, in the case of employment in a pharmacy. As used in this subsection, "direct supervision" means a supervising pharmacist
(A) is physically present in the area or location where the pharmacy technician is performing routine drug dispensing functions, and (B) conducts in-process and final checks
on the pharmacy technician's performance.
(c) The department shall, upon authorization of the commission, certify as a pharmacy technician any person who meets the requirements for registration as a pharmacy
technician, pursuant to subsection (b) of this section, and who holds a certification from
the Pharmacy Technician Certification Board or any other equivalent pharmacy technician certification program approved by the department.
(d) The fee required by section 20-601 shall accompany an application for registration under this section. A registration as a pharmacy technician shall be valid for one
year and may be renewed upon application and payment of the fee required by section
20-601.
(P.A. 98-31, S. 1: P.A. 99-175, S. 27; P.A. 04-208, S. 2.)
History: P.A. 99-175 made technical changes in Subsecs. (a) and (b); P.A. 04-208 amended Subsec. (a) by adding "or
certified with", added new Subsec. (c) providing for the certification of pharmacy technicians, and relettered existing
Subsec. (c) as Subsec. (d), effective June 3, 2004.
Sec. 20-599. (Formerly Sec. 20-174a). Continuing education: Definitions. As
used in this section and section 20-600:
(1) "Accredited continuing professional education" means any education of pharmacists which is designed to maintain professional competence in the practice of pharmacy and which is provided by an organization, institution or agency approved by the
commission. Such education may include, but is not limited to, courses concerning: (A)
The social, economic, behavioral, legal, administrative and managerial aspects of health
care; (B) the properties and actions of drugs and dosage forms; (C) the etiology, characteristics, therapeutics and prevention of the disease states; (D) the pharmaceutical monitoring and management of patients; and (E) other areas of information unique to specialized types of professional pharmacy practice;
(2) "Certificate of continuing education units" means a document issued to a pharmacist by an organization, institution or agency approved by the commission which
offers accredited continuing professional education, which (A) certifies that the pharmacist has satisfactorily completed a specified number of continuing education units, and
(B) bears the name of such organization, institution or agency, the title of the program,
the dates during which the program was conducted, the number of continuing education
units satisfactorily completed and the signature of the director of such organization,
institution or agency or the director's authorized agent;
(3) "Continuing education unit" means ten contact hours of participation in accredited continuing professional education;
(4) "Contact hours" means fifty to sixty minutes of participation in accredited continuing professional education;
(5) "Retired pharmacist" means a pharmacist who is at least sixty-two years of age
and no longer actively engaged in the practice of pharmacy; and
(6) "Inactive license" means a license that is issued, in the same manner and for the
same fee as specified in this chapter for a license to practice pharmacy, to a retired
pharmacist which license does not authorize the retired pharmacist to practice pharmacy
and on which the word "inactive" is printed or stamped.
(P.A. 87-401, S. 1, 4; P.A. 89-265, S. 1; P.A. 95-264, S. 24; P.A. 99-175, S. 28.)
History: P.A. 89-265 added definitions of "retired pharmacist" and "inactive license" as Subdivs. (6) and (7), renumbering former Subdiv. (6) as (8); P.A. 95-264 deleted definitions of "commission" and "department", renumbering remaining Subdivs. as necessary; Sec. 20-174a transferred to Sec. 20-599 in 1997; P.A. 99-175 made technical and gender
neutral changes and added Subpara. indicators in Subdivs. (1) and (2).
Sec. 20-600. (Formerly Sec. 20-174b). Continuing education: Requirements;
renewal of licenses; regulations. (a) Except as provided in subsections (b), (c), (f) and
(g) of this section, the commission shall not authorize the department to renew a license
to practice pharmacy as a pharmacist unless the pharmacist applying for the renewal
submits a statement signed under the penalty of false statement that the pharmacist has
satisfactorily completed not less than fifteen contact hours of accredited continuing
professional education in the previous calendar year immediately preceding expiration
of the license. Not less than five contact hours of the annual continuing education requirement shall be earned by attendance at a live presentation of an accredited continuing
professional education program. At least one of the five contact hours earned by attendance at a live presentation shall be on the subject matter of pharmacy law or drug law.
(b) The provisions of this section shall not apply to a pharmacist who applies for
the first renewal of a license to practice pharmacy.
(c) A pharmacist submitting an application for renewal of a license to practice pharmacy, whose license has lapsed and who has not held a license authorized by the commission and issued by the department for more than two years, shall submit a statement
signed under the penalty of false statement that the pharmacist has satisfactorily completed the requirements of this section in each of the years in the two-year period prior
to the year of the application for renewal.
(d) A pharmacist who applies for renewal of a license to practice pharmacy shall
retain all certificates of approved continuing education units for a period of not less than
three years after the date on which such license is renewed. A pharmacist shall, upon
the request of the department, and to satisfy the results of a random audit, make such
certificates available to the department for purposes of verification.
(e) Continuing education units earned in one calendar year shall not be carried forward into the next calendar year for the purpose of fulfilling the subsequent year's
accredited continuing professional education requirement for license renewal.
(f) A pharmacist who was unable to comply with the requirements of this section
for reasons such as illness, incapacity or other extenuating circumstances may apply for
a waiver of the requirements of this section or for an extension of time to fulfill the
requirements of this section. A pharmacist who requests such a waiver or extension of
time shall submit the request, in writing, to the department with the license renewal
application. The department shall forward such a request to the commission for its consideration. If the commission waives the requirements of this section, the commission
shall authorize the department to renew the license of such a pharmacist. If the commission extends the time for compliance with the requirements of this section, the commission shall authorize the department to renew the license, subject to the pharmacist's
complying with the requirements of this section within the extended time period. If the
pharmacist fails to comply with such requirements within the extended time period, the
commission shall revoke or suspend the license.
(g) The commission may authorize the department to waive the requirements of this
section and renew the license of a retired pharmacist provided the license is designated as
an inactive license. A retired pharmacist holding an inactive license shall be required
to obtain thirty hours of continuing education, not less than ten hours of which shall be
earned by attendance at a live presentation, and apply for and receive a license to practice
pharmacy issued pursuant to sections 20-570 to 20-630, inclusive, before the retired
pharmacist reenters the active practice of pharmacy.
(h) The commissioner, with the advice and assistance of the commission, may adopt
regulations, in accordance with chapter 54, to carry out the provisions of this section.
(P.A. 87-401, S. 2, 4; P.A. 89-265, S. 2; P.A. 95-264, S. 25; P.A. 99-175, S. 29; P.A. 02-48, S. 2.)
History: P.A. 89-265 made technical changes in Subsec. (f) and added Subsec. (g) re waiver of requirements for
retired pharmacists obtaining inactive license and relettered the remaining Subsecs; P.A. 95-264 deleted reference to the
requirement of ten hours of continuing education per year before 1990, amended provisions relative to waiver of the
requirement, permitted the extension of the time to complete continuing education credits and set the requirements for a
retired pharmacist to renew his license; Sec. 20-174b transferred to Sec. 20-600 in 1997; P.A. 99-175 made technical and
gender neutral changes and amended Subsec. (g) to replace reference to Sec. 20-625 with reference to Sec. 20-630; P.A.
02-48 amended Subsec. (a) by adding requirement that at least one of the five required contact hours of annual continuing
education earned by attendance at a live presentation be on the subject matter of pharmacy law or drug law.
Sec. 20-601. Fees. The department shall collect the following nonrefundable fees:
(1) The fee for issuance of a pharmacist license is one hundred dollars, payable at
the date of application for the license.
(2) The fee for applying to take the pharmacist license examination required in
section 20-590 and in section 20-591 is one hundred fifty dollars, payable at the date
of application for the pharmacist license.
(3) The fee for renewal of a pharmacist license is the professional services fee for
class A, as defined in section 33-182l. Before the commission grants a license to an
applicant who has not held a license authorized by the commission within five years of
the date of application, the applicant shall pay the fees required in subdivisions (1) and
(2) of this section.
(4) The fee for issuance of a pharmacy license is six hundred dollars.
(5) The fee for renewal of a pharmacy license is one hundred fifty dollars.
(6) The late fee for an application for renewal of a license to practice pharmacy, a
pharmacy license or a permit to sell nonlegend drugs is the amount set forth in section
21a-4.
(7) The fee for notice of a change in officers or directors of a corporation holding
a pharmacy license is thirty dollars for each pharmacy license held. A late fee for failing
to give such notice within ten days of the change is twenty-five dollars in addition to
the fee for notice.
(8) The fee for filing notice of a change in name, ownership or management of a
pharmacy is forty-five dollars. A late fee for failing to give such notice within ten days
of the change is twenty-five dollars in addition to the fee for notice.
(9) The fee for application for registration as a pharmacy intern is thirty dollars.
(10) The fee for application for a permit to sell nonlegend drugs is seventy dollars.
(11) The fee for renewal of a permit to sell nonlegend drugs is fifty dollars.
(12) The late fee for failing to notify the commission of a change of ownership,
name or location of the premises of a permit to sell nonlegend drugs within five days
of the change is ten dollars.
(13) The fee for issuance of a nonresident pharmacy certificate of registration is six
hundred dollars.
(14) The fee for renewal of a nonresident pharmacy certificate of registration is one
hundred fifty dollars.
(15) The fee for application for registration as a pharmacy technician is fifty dollars.
(16) The fee for renewal of a registration as a pharmacy technician is twenty-five
dollars.
(17) The fee for issuance of a temporary permit to practice pharmacy is one hundred
dollars.
(P.A. 95-264, S. 26; P.A. 98-31, S. 6; P.A. 99-175, S. 30; P.A. 00-182, S. 9.)
History: P.A. 98-31 added new Subdivs. (13) and (14) re fees for pharmacy technician registrations; P.A. 99-175
made technical changes, added new Subdiv. (13) to include six-hundred-dollar fee for issuance of nonresident pharmacy
certificate and added new Subdiv. (14) to include one-hundred-fifty-dollar fee for renewal of nonresident pharmacy certificate, renumbering remaining Subdivs. accordingly; P.A. 00-182 changed "shall be" to "is" throughout and added Subsec.
(17) re fee for a temporary permit to practice pharmacy.
Secs. 20-602 to 20-604. Reserved for future use.
PART III*
PRACTICE OF PHARMACY
*See Sec. 18-81q re return to vendor pharmacies of unused drug products by Department of Correction for repackaging and/or redispensing and reimbursement.
Sec. 20-605. Practice of pharmacy without license or temporary permit prohibited. No individual may engage in the practice of pharmacy unless the individual
holds a current license or temporary permit to practice pharmacy issued by the department.
(P.A. 95-264, S. 27; P.A. 99-175, S. 31; P.A. 00-182, S. 10.)
History: P.A. 99-175 made a technical change; P.A. 00-182 added "or temporary permit".
Sec. 20-606. (Formerly Sec. 20-178). Use of the title "pharmacist". A pharmacist who conforms to the regulations of the commissioner, adopted with the advice and
assistance of the commission in accordance with chapter 54, may have, use and exhibit
the title "pharmacist" in the practice of pharmacy.
(1949 Rev., S. 4476; P.A. 95-264, S. 28; P.A. 99-175, S. 32.)
History: P.A. 95-264 deleted references to licensed and assistant pharmacists and provisions which had prohibited
pharmacist supervising more than one pharmacy and had allowed assistant pharmacist to work under supervision of pharmacist or during his temporary absence; Sec. 20-178 transferred to Sec. 20-606 in 1997; P.A. 99-175 replaced provision
requiring adoption of regulations by commission with provision requiring adoption of regulations consistent with chapter
54 by commissioner with advice and assistance of commission.
Sec. 20-607. (Formerly Sec. 20-173). Certificate of license, temporary permit
or registration to be available for inspection. Each person practicing as a pharmacist,
pharmacy intern or pharmacy technician shall at all times have available for inspection
by an inspector of the department a current certificate of license or temporary permit
to practice pharmacy or a current registration to act as a pharmacy intern or pharmacy
technician.
(1949 Rev., S. 4477; P.A. 95-264, S. 29; P.A. 98-31, S. 7; P.A. 99-175, S. 33; P.A. 00-182, S. 11.)
History: P.A. 95-264 deleted reference to licensed or assistant pharmacist, deleted requirement that pharmacist must
display certificate in the place he practices and required that a current certificate of license to practice must be available
for inspection at all times; Sec. 20-173 transferred to Sec. 20-607 in 1997; P.A. 98-31 added provisions re pharmacy interns
and pharmacy technicians; P.A. 99-175 made a technical change; P.A. 00-182 added "or temporary permit".
Sec. 20-608. (Formerly Sec. 20-174). Use of certificate of license, temporary
permit or display document by unlicensed person prohibited. A pharmacist who
permits such pharmacist's certificate of license, temporary permit or display document
to be used by an unlicensed person for unlawful use shall be fined one hundred dollars and
shall be subject to other disciplinary proceedings within the authority of the commission.
(1949 Rev., S. 4478; P.A. 95-264, S. 30; P.A. 99-175, S. 34; P.A. 00-182, S. 12.)
History: P.A. 95-264 deleted reference to licensed or assistant pharmacist, made prohibition applicable to a display
document, eliminated forfeiture as a penalty and substituted disciplinary proceedings as a penalty; Sec. 20-174 transferred
to Sec. 20-608 in 1997; P.A. 99-175 made technical and gender neutral changes; P.A. 00-182 added language re temporary permit.
See Sec. 19a-70 re violation of regulations governing distribution of biologic products during an emergency as grounds
for suspension, revocation or annulment of a license or certificate.
See Sec. 30-101 re forfeiture of liquor permit and pharmacist's license for allowing on-premises consumption of alcohol.
Sec. 20-609. (Formerly Sec. 20-184). Pharmacy license to be posted. Business
which is not a pharmacy prohibited from using words, displays or symbols indicating it is a pharmacy. (a) A pharmacy license shall be conspicuously posted within the
pharmacy.
(b) Any person owning, managing or conducting any store, shop or place of business
not being a pharmacy who exhibits within or upon the outside of such store, shop or
place of business, or includes in any advertisement the words "drug store", "pharmacy",
"apothecary", "drug", "drugs", "medicine shop", or any combination of such terms or
any other words, displays or symbols indicating that such store, shop or place of business
is a pharmacy shall be fined not more than two hundred dollars or imprisoned not more
than thirty days or both.
(1949 Rev., S. 4485; P.A. 95-264, S. 31.)
History: P.A. 95-264 inserted provisions as Subsec. (a) requiring pharmacy license to be posted in pharmacy, designated
previous provisions as Subsec. (b), clarified the prohibition on use of specified terms, displays or symbols and deleted
obsolete provisions prohibiting the use of show bottles and globes; Sec. 20-184 transferred to Sec. 20-609 in 1997.
Annotation to former section 20-184:
Cited. 141 C. 288.
Sec. 20-610. (Formerly Sec. 20-166). Dispensing or retail sale of legend drugs,
legend devices and certain other drugs by other than pharmacies and hospitals,
prohibited. (a) No legend drug, legend device or drugs listed in subsection (b) of this
section may be dispensed or sold at retail except (1) in a pharmacy, (2) by a hospital
licensed under sections 19a-490 to 19a-503, inclusive, to an employee of the hospital
when prescribed by a prescribing practitioner for the employee or the employee's spouse
or dependent children, or (3) by such hospital to a retiree of such hospital or the retiree's
spouse in accordance with the retiree's retirement or pension plan.
(b) The following drugs may not be sold at retail except as permitted in subsection
(a) of this section: (1) Injectable or ingestible antibiotics; (2) injectable biologicals; (3)
sulfonamides and their compounds which are designed to be taken into the stomach for
systemic action; (4) injectable or ingestible corticosteroids; or (5) camphorated tincture
of opium.
(c) Any person who violates any provision of this section shall be fined not less
than one hundred dollars nor more than five hundred dollars.
(1949 Rev., S. 4465; 1951, 1955, S. 2237d; 1959, P.A. 616, S. 53; 1963, P.A. 367; February, 1965, P.A. 319; 1967,
P.A. 109, S. 3; 555, S. 77; 1971, P.A. 134; June, 1971, P.A. 8, S. 60; 1972, P.A. 223, S. 7; P.A. 73-670, S. 1, 2; P.A. 74-100, S. 1, 2; P.A. 76-286; P.A. 77-614, S. 199, 610; P.A. 79-16; P.A. 81-107; P.A. 85-241, S. 2; P.A. 86-403, S. 41, 132;
P.A. 89-251, S. 95, 203; P.A. 94-36, S. 33, 42; P.A. 95-264, S. 32; P.A. 01-65, S. 1, 2.)
History: 1959 act increased permit fee for towns with population of less than five thousand from three dollars and
doubled fee for towns with population of more than five thousand; 1963 act added corticosteroids and mild silver protein
to, and deleted argyrol from, provision listing items prohibited from sale; 1965 act added penalty proviso for failure to
renew in timely fashion and prohibited issuance of renewal permit until fee and penalty paid; 1967 acts added references
to dentist's prescriptions and deleted descriptive references to opium, morphine and codeine content of preparations and
compounds and substituted "any controlled drug as defined in section 19-443, except as permitted in sections 20-180 and
part II of chapter 359" and added similar reference to "controlled drug" in list of items prohibited for sale by stores or
shops not licensed as pharmacies; 1971 acts required permittee for sale of drugs, etc. to be at least twenty-one, allowed
imposition of penalty for failure to record change in permittee with commission of pharmacy and doubled permit fees;
1972 act established separate renewal fee of ten dollars; P.A. 73-670 added exception to prohibition of retail sales except
by pharmacist for methadone sold by hospitals; P.A. 74-100 expanded exception to include sales by hospitals to employees
for themselves or their dependents; P.A. 76-286 deleted age, citizenship and moral character requirements for permit
holders, deleted provision re sales by store not licensed as a pharmacy under special permit, replaced differential fees based
on population with single fee of thirty-five dollars, raised renewal fee from ten to twenty-five dollars, made penalties ten
dollars rather than fifty per cent of permit fee, deleted provision allowing appeal by person who has been refused a permit
and prohibited sales of "legend drugs" as defined in Sec. 20-184a; P.A. 77-614 replaced commission's regulations with
regulations "established under this chapter", effective January 1, 1979; P.A. 79-16 deleted exception re sales of methadone
by hospitals; P.A. 81-107 qualified as "injectable" or "ingestible" the antibiotics and corticosteroids which may not be
stored, kept, sold or offered for sale by stores or shops other than licensed pharmacies; P.A. 85-241 clarified that the
sale of veterinary medicines, poisons or chemicals by permittees is not prohibited and substituted references to licensed
practitioners for references to physicians and dentists; P.A. 86-403 made technical change; P.A. 89-251 increased the
original fee from thirty-five dollars to seventy dollars and increased the renewal fee from twenty-five dollars to fifty dollars;
P.A. 94-36 deleted the provision allowing the collection of late license renewal fees, effective January 1, 1995; P.A. 95-264 divided sections into Subsecs., substituted reference to legend drugs for reference to substances used to compound
medicine, deleted provisions re sale of patent medicines and specified certain types of drugs to be sold only as permitted
in Subsec. (a) in new provision designated as Subsec. (b); Sec. 20-166 transferred to Sec. 20-610 in 1997; P.A. 01-65
amended Subsec. (a) by designating existing exceptions as Subdivs. (1) and (2) and adding new Subdiv. (3) re retirees of
hospital, effective June 6, 2001.
See Sec. 21a-4(c) re fines for late license renewals.
Sec. 20-611. (Formerly Sec. 20-175b). Advertising legend drug prices. A pharmacist or any person holding a pharmacy license (1) may advertise the price of any
legend drug sold at retail based on the prescription of a prescribing practitioner, provided,
each such advertisement shall clearly state the period during which the advertised price
or prices shall remain in effect and shall not contain any statement indicating that the
advertised price or prices are subject to change without notice; and (2) shall disclose,
upon request, the price of any such legend drug to any prospective purchaser.
(P.A. 75-95, S. 1, 3; P.A. 95-264, S. 33.)
History: P.A. 95-264 made technical changes and changed references to "drug, medicine or chemical" to "legend drug";
Sec. 20-175b transferred to Sec. 20-611 in 1997.
See chapter 418 re Uniform Food, Drug and Cosmetic Act.
See chapter 419 re retail drug control.
Sec. 20-612. Only pharmacy may accept prescription for dispensing. Subject
to the provisions of subsection (d) of section 20-614, only a pharmacy shall accept a
prescription for dispensing. No employee, personnel or owner of a place of business or
establishment not licensed as a pharmacy may accept a prescription for transfer to or
for collection for a pharmacy.
(P.A. 95-264, S. 35; P.A. 04-107, S. 2.)
History: P.A. 04-107 amended section so as to make it subject to the provisions of Sec. 20-614(d), which provides for
electronic data intermediaries.
Sec. 20-613. (Formerly Sec. 21a-308). Dispensing of drug or legend device pursuant to prescription only; exceptions. Emergency dispensing of drug or device in
care-giving, correctional or juvenile training institutions; regulations. Pharmacy
technicians. Prescribing practitioner authorized to dispense own prescription,
when. (a) Except as provided in subsections (b) and (d) of this section, a drug or a legend
device may be dispensed pursuant to a prescription only in a pharmacy or institutional
pharmacy by a pharmacist or by a pharmacy intern when acting under the direct supervision of a pharmacist, or by an individual holding a temporary permit.
(b) In care-giving institutions and correctional or juvenile training institutions in
emergency situations when the pharmacist is not available for the dispensing of drugs
or devices from the institutional pharmacy, the prescription shall be reviewed by the
nursing supervisor or a physician before administration of the drug or device and recorded with the pharmacist in its original form or a copy thereof. After the required review
in such emergency situations, the person authorized by the institution may dispense
drugs and devices from the institutional pharmacy pursuant to regulations adopted by
the commissioner, with the advice and assistance of the commission, in accordance with
chapter 54.
(c) A pharmacy technician in a pharmacy or an institutional pharmacy may assist,
under the direct supervision of a pharmacist, in the dispensing of drugs and devices. A
person whose license to practice pharmacy is under suspension or revocation shall not
act as a pharmacy technician.
(d) Nothing in sections 20-570 to 20-630, inclusive, shall prevent a prescribing
practitioner from dispensing the prescribing practitioner's own prescriptions to the prescribing practitioner's own patients when authorized within the scope of the prescribing
practitioner's own practice and when done in compliance with sections 20-14c to 20-14g, inclusive.
(1969, P.A. 593, S. 18; P.A. 81-200, S. 2; P.A. 91-47, S. 2; P.A. 95-264, S. 34; P.A. 99-175, S. 35; P.A. 00-182, S. 13.)
History: P.A. 81-200 added Subsecs. (f) and (g) specifying the functions which may be performed by supportive
personnel and requiring the commissioner of consumer protection to adopt regulations governing the number and activities
of such personnel in institutional pharmacies; Sec. 19-504j transferred to Sec. 21a-308 in 1983; P.A. 91-47 authorized
supportive personnel in licensed pharmacies to compound and dispense medications and to perform other tasks and provided
for the adoption of regulations by the commissioner of consumer protection for supportive personnel in licensed pharmacies;
P.A. 95-264 deleted provisions governing refills, replaced provisions re permissible actions of support personnel with
provision re pharmacy technicians, added provision re dispensing of prescriptions by prescribing practitioners, changed
references to "drugs" in Subsec. (b) to "drugs and devices" and made technical changes; Sec. 21a-308 transferred to Sec.
20-613 in 1997; P.A. 99-175 made technical and gender neutral changes, amended Subsec. (b) to add provision requiring
adoption of regulations to be consistent with chapter 54 and amended Subsec. (d) to replace reference to Sec. 20-625 with
reference to Sec. 20-630; P.A. 00-182 amended Subsec. (a) by adding language re individual holding a temporary permit.
Sec. 20-614. (Formerly Sec. 20-184b). Prescriptions: Form and content. Electronic data intermediaries. (a) A prescription shall be transmitted in either an oral,
written or electronic manner to a pharmacy.
(b) Whenever a pharmacy, or an institutional pharmacy in a hospital dispensing a
drug or device for outpatient use or dispensing a drug or device that is prescribed for
an employee of the hospital or for the employee's spouse or dependent children, receives
an oral or electronically-transmitted prescription, except for a controlled drug, as defined
in section 21a-240, the pharmacist or pharmacy intern shall, not later than the end of
the business day when the prescription was received, record the prescription on a prescription form or computerized printed record including: (1) The name and address of
the prescribing practitioner; (2) the date of the prescription; (3) the name, dosage form,
strength, where applicable, and the amount of the drug prescribed; (4) the name and
address of the patient or, for veterinary prescriptions, the name and address of the owner
and the species of the animal; (5) the directions for use; (6) any required cautionary
statements; and (7) the number of times the prescription may be refilled, including the
use of refill terms "PRN" and "ad lib" in lieu of a specific number of authorized refills.
(c) A written prescription shall bear: (1) The written signature of the prescribing
practitioner or shall comply with the requirements of section 19a-509c; (2) the address
of the practitioner; (3) the date of the prescription; (4) the name, dosage form, strength,
where applicable, and amount of the drug prescribed; (5) the name and address of the
patient or, for veterinary prescriptions, the name and address of the owner and the species
of the animal; (6) the directions for use; (7) any required cautionary statements; and (8)
the number of times the prescription may be refilled, including the use of refill terms
"PRN" and "ad lib" in lieu of a specific number of authorized refills. No written prescription form for a schedule II substance may contain an order for any other legend drug or
device.
(d) (1) As used in this subsection, "electronic data intermediary" means an entity
that provides the infrastructure that connects the computer systems or other electronic
devices utilized by prescribing practitioners with those used by pharmacies in order to
facilitate the secure transmission of electronic prescription orders, refill authorization
requests, communications and other patient care information between such entities.
(2) An electronic data intermediary may transfer electronically transmitted data
between a prescribing practitioner licensed and authorized to prescribe and a pharmacy
of the patient's choice, licensed pursuant to this chapter or licensed under the laws of
any other state or territory of the United States. Electronic data intermediaries shall
not alter the transmitted data except as necessary for technical processing purposes.
Electronic data intermediaries may archive copies of only that electronic data related
to such transmissions necessary to provide for proper auditing and security of such
transmissions. Such data shall only be maintained for the period necessary for auditing
purposes. Electronic data intermediaries shall maintain patient privacy and confidentiality of all archived information as required by state and federal law.
(3) No electronic data intermediary shall operate without the approval of the Commissioner of Consumer Protection. An electronic data intermediary seeking approval
shall apply to the Commission of Pharmacy in the manner prescribed by the commissioner. The commissioner, with the advice and assistance of the commission, shall adopt
regulations, in accordance with the provisions of chapter 54, to establish criteria for the
approval of electronic data intermediaries, including requirements for (A) the procedures to be used for the transmission and retention of prescription data by an intermediary
and (B) mechanisms to be used by an intermediary to safeguard the confidentiality of
such data.
(1969, P.A. 48, S. 2; P.A. 75-20; P.A. 77-165, S. 2; P.A. 82-419, S. 43, 47; P.A. 87-589, S. 62, 87; P.A. 95-264, S. 36;
P.A. 99-175, S. 36; P.A. 04-107, S. 1.)
History: P.A. 75-20 deleted requirement that prescriptions, whether oral and then recorded or written, contain narcotic
registry number, if applicable, deleted exception for controlled drugs in requirements for written prescriptions and substituted "species" for "breed"; P.A. 77-165 limited to one the number of prescriptions allowed per blank; P.A. 82-419 amended
section to allow more than one prescription on a blank except in case of schedule II substance where previously prohibition
against multiple prescriptions on a blank was absolute; P.A. 87-589 added "including the use of refill terms "PRN" and
"ad lib" in lieu of a specific number of authorized refills"; P.A. 95-264 divided section into Subsecs., adding new provision
as Subsec. (a) permitting electronically transmitted prescriptions, made technical changes and required pharmacies to
record electronically transmitted prescriptions; Sec. 20-184b transferred to Sec. 20-614 in 1997; P.A. 99-175 made technical
changes and added Subdiv. indicators to Subsec. (b); P.A. 04-107 added Subsec. (d) providing for electronic data intermediaries.
Sec. 20-615. (Formerly Sec. 20-184c). Prescriptions: Pharmacy to assign serial
number and maintain records. Transfer of records to another pharmacy. (a) An
institutional pharmacy dispensing a drug in circumstances described in subsection (g)
of this section and a pharmacy shall assign and record a serial number to each prescription
that it fills and shall keep all written prescriptions and the record of oral and electronically-transmitted prescriptions required in section 20-614 in numerical order in a suitable file or ledger for a period of not less than three years. The records shall indicate
the date of filling, the name and address of the prescribing practitioner, the name and
address of the patient or the name and address of the owner of an animal for whom the
prescription was written and the species of the animal and the initials of the pharmacist
who dispensed the drug.
(b) A refill of a prescription shall be recorded on the face or back of the original
prescription.
(c) Records maintained under this section shall be made available for inspection
upon request of any authorized agent of the commissioner or other person authorized
by law.
(d) When a pharmacy closes temporarily or permanently, the pharmacy shall, in
the interest of public health, safety and convenience, make its complete prescription
records immediately available to a nearby pharmacy and post a notice of this availability
on the window or door of the closed pharmacy.
(e) Any violation of this section shall be punishable as provided in section 20-581.
(f) This section shall not apply to records maintained in accordance with regulations
adopted pursuant to section 20-576 or 21a-244, to the extent such regulations are inconsistent with this section.
(g) When an institutional pharmacy in a hospital dispenses a drug or device for
outpatient use or dispenses a drug or device that is prescribed for an employee of the
hospital or for the employee's spouse or dependent children, the provisions of subsections (a), (b), (c) and (e) of this section shall apply.
(1969, P.A. 29; 1971, P.A. 156; P.A. 77-277, S. 6; 77-614, S. 206, 610; P.A. 95-264, S. 37; P.A. 99-175, S. 37.)
History: 1971 act allowed recording of refill on back of original prescription; P.A. 77-277 added Subsec. (b) excepting
certain records from provisions of section; P.A. 77-614 replaced agents of commission of pharmacy with agents of consumer
protection commissioner as inspectors of records, effective January 1, 1979; P.A. 95-264 added provisions requiring a
pharmacy to record a serial number for each prescription it fills, made technical changes and added a new Subsec. (g) re
dispensing of drug or device by hospital pharmacy for outpatient use or for hospital employee or family member; Sec. 20-184c transferred to Sec. 20-615 in 1997; P.A. 99-175 amended Subsec. (c) to make technical changes.
Annotation to former section 20-184c:
Cited. 207 C. 698, 703.
Sec. 20-616. (Formerly Sec. 20-184d). Prescriptions: Refills; transfers. (a) Except as provided in subsection (b) of this section, a prescription may be refilled only
upon the written, oral or electronically-transmitted order of a prescribing practitioner.
(b) A pharmacist may exercise his professional judgment in refilling a prescription
that is not for a controlled drug, as defined in section 21a-240, without the authorization
of the prescribing practitioner, provided (1) the pharmacist is unable to contact such
practitioner after reasonable effort, (2) failure to refill the prescription might result in an
interruption of a therapeutic regimen or create patient suffering, and (3) the pharmacist
informs the patient or representative of the patient at the time of dispensing that the
refill is being provided without such authorization and informs the practitioner at the
earliest reasonable time that authorization of the practitioner is required for future refills.
Prescriptions may be refilled once pursuant to this subsection for a quantity of drug not
to exceed a seventy-two hour supply.
(c) Any prescription that is not for a controlled drug, as defined in section 21a-240,
may be transferred orally or electronically between pharmacies, provided:
(1) The prescribing practitioner has authorized the original prescription to be refilled in accordance with subsection (a) of this section;
(2) The pharmacist transferring the prescription shall cancel the original prescription in such pharmacist's records and shall indicate in such records the name of the
pharmacy to which the prescription is transferred and the date of the transfer, provided,
such cancellation shall not be required in the case of any transfer between pharmacies
which electronically access the same prescription records and utilize the same computer
or other electronic prescription transfer system; and
(3) The pharmacist receiving the prescription shall indicate in such pharmacist's
records, in addition to any other information required by law, (A) the fact that the prescription has been transferred and the names of the transferring pharmacy and pharmacist, (B) the date of issuance and the prescription number of the original prescription,
(C) the date the original prescription was first dispensed, (D) the number of refills authorized by the original prescription and the complete refill record for the prescription as
of the date of the transfer, and (E) the number of valid refills remaining as of the date
of the transfer.
(P.A. 91-164, S. 1; P.A. 95-264, S. 38; P.A. 97-64, S. 1.)
History: P.A. 95-264 added new Subsec. (a) re refills, designated existing provisions as Subsec. (b) and made technical
changes; Sec. 20-184d transferred to Sec. 20-616 in 1997; P.A. 97-64 made technical changes in Subsec. (b) and added
Subsec. (c) re transfer of prescriptions.
Sec. 20-617. (Formerly Sec. 20-184e). Prescriptions: Notation of drug quantities and expiration dates required on labels. Each pharmacist shall include on the
label of each prescription container: (1) The quantity of prescribed drug placed in such
container, in addition to any other information required by law; and (2) a prominently
printed expiration date based on the manufacturer's recommended conditions of use
and storage that can be read and understood by the ordinary individual. The expiration
date required pursuant to subdivision (2) of this section shall be no later than the expiration date determined by the manufacturer.
(P.A. 93-94; P.A. 99-49; 99-175, S. 38; P.A. 00-182, S. 3.)
History: Sec. 20-184e transferred to Sec. 20-617 in 1997; P.A. 99-49 made a technical change, added Subdiv. indicators
and added provision requiring prescription drug container label to include drug's expiration date; P.A. 99-175 made
technical changes and deleted reference to Sec. 20-590; P.A. 00-182 added language re manufacturer's recommended
conditions of use and storage and deleted language re customary conditions of purchase, and use and storage and re absence
of contrary data.
Sec. 20-618. (Formerly Sec. 21a-107). Repackaged drugs not considered misbranded, when. Notwithstanding the provisions of section 21a-106 concerning misbranding of drugs or devices, a drug shall not be considered misbranded when repackaged by a pharmacy or an institutional pharmacy into stock packages for use within the
pharmacy or the institutional pharmacy, provided the stock packages contain a label
indicating the drug's name, strength, lot number, manufacturer and expiration date,
if any.
(P.A. 79-116, S. 2; P.A. 95-264, S. 39.)
History: Sec. 19-226a transferred to Sec. 21a-107 in 1983; P.A. 95-264 made technical changes; Sec. 21a-107 transferred
to Sec. 20-618 in 1997.
Sec. 20-619. (Formerly Sec. 20-185a). Substitution of generic drugs. Regulations. (a) For the purposes of section 20-579 and this section:
(1) "Brand name" means the proprietary or trade name selected by the manufacturer
and placed upon a drug product, its container, label or wrapping at the time of packaging;
(2) "Generic name" means the established name designated in the official United
States Pharmacopoeia/National Formulary, official Homeopathic Pharmacopoeia of the
United States, or official United States adopted names or any supplement to any of them;
(3) "Therapeutically equivalent" means drug products that are approved under the
provisions of the federal Food, Drug and Cosmetics Act for interstate distribution and
that will provide essentially the same efficacy and toxicity when administered to an
individual in the same dosage regimen; and
(4) "Dosage form" means the physical formulation or medium in which the product
is intended, manufactured and made available for use, including, but not limited to,
tablets, capsules, oral solutions, aerosol, inhalers, gels, lotions, creams, ointments, transdermals and suppositories, and the particular form of any physical formulation or medium that uses a specific technology or mechanism to control, enhance or direct the
release, targeting, systemic absorption, or other delivery of a dosage regimen in the body.
(b) Except as limited by subsections (c) and (e) of this section, unless the purchaser
instructs otherwise, the pharmacist may substitute a generic drug product with the same
strength, quantity, dose and dosage form as the prescribed drug product which is, in the
pharmacist's professional opinion, therapeutically equivalent. When the prescribing
practitioner is not reasonably available for consultation and the prescribed drug does
not use a unique delivery system technology, the pharmacist may substitute an oral
tablet, capsule or liquid form of the prescribed drug as long as the form dispensed has
the same strength, dose and dose schedule and is therapeutically equivalent to the drug
prescribed. The pharmacist shall inform the patient or a representative of the patient,
and the practitioner of the substitution at the earliest reasonable time.
(c) A prescribing practitioner may specify in writing or by a telephonic or other
electronic communication that there shall be no substitution for the specified brand name
drug product in any prescription, provided (1) in any prescription for a Medicaid, state-administered general assistance, or ConnPACE recipient, such practitioner specifies the
basis on which the brand name drug product and dosage form is medically necessary
in comparison to a chemically equivalent generic drug product substitution, and (2) the
phrase "BRAND MEDICALLY NECESSARY", shall be in the practitioner's handwriting on the prescription form or on an electronically-produced copy of the prescription
form or, if the prohibition was communicated by telephonic or other electronic communication that did not reproduce the practitioner's handwriting, a statement to that effect
appears on the form. The phrase "BRAND MEDICALLY NECESSARY" shall not be
preprinted or stamped or initialed on the form. If the practitioner specifies by telephonic
or other electronic communication that did not reproduce the practitioner's handwriting
that there shall be no substitution for the specified brand name drug product in any
prescription for a Medicaid, state-administered general assistance, or ConnPACE recipient, written certification in the practitioner's handwriting bearing the phrase "BRAND
MEDICALLY NECESSARY" shall be sent to the dispensing pharmacy within ten days.
(d) Each pharmacy shall post a sign in a location easily seen by patrons at the counter
where prescriptions are dispensed stating that, "THIS PHARMACY MAY BE ABLE
TO SUBSTITUTE A LESS EXPENSIVE DRUG PRODUCT WHICH IS THERAPEUTICALLY EQUIVALENT TO THE ONE PRESCRIBED BY YOUR DOCTOR UNLESS YOU DO NOT APPROVE." The printing on the sign shall be in block letters
not less than one inch in height.
(e) A pharmacist may substitute a drug product under subsection (b) of this section
only when there will be a savings in cost passed on to the purchaser. The pharmacist
shall disclose the amount of the savings at the request of the patient.
(f) Except as provided in subsection (g) of this section, when a pharmacist dispenses
a substitute drug product as authorized by subsection (b) of this section, the pharmacist
shall label the prescription container with the name of the dispensed drug product. If
the dispensed drug product does not have a brand name, the prescription label shall
indicate the generic name of the drug product dispensed along with the name of the drug
manufacturer or distributor.
(g) A prescription dispensed by a pharmacist shall bear upon the label the name of
the drug in the container unless the prescribing practitioner writes "DO NOT LABEL",
or words of similar import, on the prescription or so designates in an oral or electronic
transmission of the prescription.
(h) Neither the failure to instruct by the purchaser as provided in subsection (b) of
this section nor the fact that a sign has been posted as provided in subsection (d) of this
section shall be a defense on the part of a pharmacist against a suit brought by any such
purchaser.
(i) The commissioner, with the advice and assistance of the commission, shall adopt
regulations, in accordance with chapter 54, to carry out the provisions of this section.
(P.A. 76-166, S. 1, 8; P.A. 94-32, S. 1; P.A. 95-264, S. 40; P.A. 99-175, S. 39; June Sp. Sess. P.A. 00-2, S. 42, 53; P.A.
04-76, S. 31.)
History: P.A. 94-32 added definition of "dosage form" and made technical changes; P.A. 95-264 made technical changes
in definitions, deleted definition of "substitute" and added Subsecs. (b) to (i) re substitutions; Sec. 20-185a transferred to
Sec. 20-619 in 1997; P.A. 99-175 made technical changes and amended Subsec. (i) to add provision requiring adoption
of regulations to be consistent with chapter 54; June Sp. Sess. P.A. 00-2 amended Subsec. (c) by adding provisions requiring
practitioner to specify basis of medical necessity in prescriptions for assistance recipients, by deleting "NO SUBSTITUTION" phrase requirements and by making conforming and technical changes, effective July 1, 2000; P.A. 04-76 amended
Subsec. (c) by deleting references to "general assistance".
Sec. 20-620. (Formerly Sec. 20-185g). Pharmacist's duties towards Medicaid
recipients: To obtain, record and maintain pertinent patient information about
the recipient; to undertake a review of the drugs previously dispensed to the recipient and to offer to discuss the drugs to be dispensed and to counsel the recipient
on their correct usage. Exception. (a) Prior to or simultaneously with dispensing a
prescription in accordance with sections 17b-260 to 17b-262, inclusive, and 17b-264
to 17b-285, inclusive, a pharmacist or the designee of the pharmacist shall make a reasonable effort to obtain, record and maintain, in a manner deemed appropriate by the pharmacist, the following information regarding the individual receiving such prescription:
(1) Name, address, telephone number, date of birth or age and gender; (2) individual
history where significant, including disease states, known allergies and drug reactions;
(3) a comprehensive list of drugs and relevant devices dispensed by the pharmacy within
the last one hundred eighty days; and (4) the pharmacist's comments relevant to the
individual's drug therapy.
(b) Prior to or simultaneously with dispensing a drug to an individual eligible for
benefits in accordance with sections 17b-260 to 17b-262, inclusive, and 17b-264 to 17b-285, inclusive, a pharmacist shall undertake a review of drugs dispensed to the individual
by the pharmacy during the previous one hundred eighty days. The review shall include
screening for potential drug therapy problems due to therapeutic duplication, a contraindication between a drug and a disease, the interaction of one drug with another, incorrect
drug dosage or duration of drug treatment, the interaction of a drug and an allergy,
clinical abuse or misuse and any other significant clinical issues relating to the appropriate use of drugs. Such review shall be based upon current standards and information
consistent with that provided in the following resources: The American Hospital Formulary Service Drug Information, the United States Pharmacopoeia Drug Information,
the American Medical Association Drug Evaluations and the peer-reviewed medical
literature.
(c) Prior to or simultaneously with dispensing drugs to individuals eligible for benefits in accordance with sections 17b-260 to 17b-262, inclusive, and 17b-264 to 17b-285, inclusive, a pharmacist shall, whenever practicable, offer in person to discuss the
drugs to be dispensed and to counsel the client on their usage, except when the person
obtaining the prescription is other than the person named on the prescription form or
the pharmacist determines it is appropriate to make such offer in writing. Any such
written offer shall include an offer to communicate with the client either in person at
the pharmacy or by telephone.
(d) The discussion and counseling offered in accordance with subsection (c) of this
section shall include information deemed significant by the pharmacist based upon the
findings of the review conducted in accordance with subsection (b) of this section,
including (1) the name and description of the drug; (2) dosage form, dosage, route of
administration and duration of drug therapy; (3) special directions and precautions for
preparation, administration and use by the patient; (4) common severe side or adverse
effects or interactions and therapeutic contraindications or precautions which the pharmacist deems relevant; (5) techniques for self-monitoring drug therapy; (6) proper storage; (7) prescription refill information; and (8) action to be taken in the event of a missed
dose or adverse reaction.
(e) Nothing in this section shall be construed as requiring a pharmacist to provide
counseling or gather information when an individual receiving benefits refuses such
counseling or refuses or is unable to provide the information requested. The pharmacist
shall document the provision of counseling, a refusal by or the inability of the patient
to accept counseling or a refusal by the patient to give information. Records kept pursuant
to this subsection shall be maintained for the same length of time as prescription records
are maintained pursuant to section 20-615.
(f) The provisions of subsections (c) and (d) of this section shall not apply to a drug
dispensed to a patient of a nursing home that is in compliance with the requirements of
42 CFR 483.60.
(May Sp. Sess. P.A. 92-16, S. 41, 89; P.A. 95-264, S. 41.)
History: P.A. 95-264 moved provisions of Subsec. (d) to Subsec. (a), relettering Subsecs. as necessary and made
technical changes; Sec. 20-185g transferred to Sec. 20-620 in 1997.
Sec. 20-621. (Formerly Sec. 20-185h). Relabeling and dispensing of parenteral
medication in hospital and nursing home pharmacies: When allowed. A pharmacist
practicing in a hospital pharmacy or nursing home pharmacy may relabel and dispense
to a registered inpatient, parenteral medication, except controlled substances, dispensed
for another registered patient by a licensed pharmacy if the following requirements are
met: (1) The original medication order for the drug is discontinued; (2) the medication
is in an unopened tamper-evident package; (3) the medication is not expired; (4) the
original patient is not charged for the medication; and (5) upon receipt of the medication
by the facility from the licensed pharmacy, it is processed through the hospital's pharmacy or nursing home pharmacy.
(P.A. 93-173, S. 1.)
History: Sec. 20-185h transferred to Sec. 20-621 in 1997.
Sec. 20-622. (Formerly Sec. 20-180a). Licensed practitioners may authorize
medication to be dispensed from a hospital emergency room. When the therapeutic
needs of a patient require that medication be initiated immediately and the services of
a licensed pharmacy are not available within a five-mile radius of a hospital emergency
room, a person associated with such hospital authorized to dispense medication may
dispense up to a twenty-four-hour supply of medication, excluding controlled substances, to such patient. Such dispensing shall be authorized by a verbal order of a
licensed practitioner. For purposes of this section, "licensed practitioner" means a physician on the staff of such hospital or other prescribing practitioner associated with such
hospital who has examined such patient and determined the patient's therapeutic needs.
(P.A. 93-173, S. 2; P.A. 99-175, S. 40.)
History: Sec. 20-180a transferred to Sec. 20-622 in 1997; P.A. 99-175 made technical and gender neutral changes and
deleted reference to Sec. 20-184a.
Sec. 20-623. Sale of nonlegend drugs. Labels, packaging and contents. Penalty.
(a) No nonlegend drug may be sold at retail except at a pharmacy or at a store that has
obtained from the commission a permit to sell nonlegend drugs. Nonlegend drugs shall
be labeled and packaged in accordance with state and federal law.
(b) Any person who violates any provision of this section shall be fined not less
than one hundred dollars nor more than five hundred dollars.
(P.A. 95-264, S. 42; P.A. 99-175, S. 41.)
History: P.A. 99-175 made a technical change in Subsec. (a).
Sec. 20-624. Permit to sell nonlegend drugs. (a) Any person may apply to the
commission for a permit to sell nonlegend drugs.
(b) The commission may, in accordance with regulations adopted under sections
20-570 to 20-630, inclusive, in accordance with chapter 54, and on payment of the fee
required in section 20-601, issue to an applicant a permit to sell nonlegend drugs for
one year.
(c) A permit that has expired under this section may be renewed, on application and
payment of the renewal fee and any late fee required in section 20-601.
(d) The holder of a permit to sell nonlegend drugs shall notify the commission of
a change of ownership, name or location of the permit premises. Any holder who fails
to notify the commission of such change within five days of the change shall pay the
late fee required in section 20-601.
(e) Any nonlegend drug permit issued by the commission pursuant to this section
is nontransferable.
(P.A. 95-264, S. 43; P.A. 99-175, S. 42.)
History: P.A. 99-175 amended Subsec. (b) to replace reference to Sec. 20-625 with reference to Sec. 20-630 and add
provision requiring adoption of regulations to be consistent with chapter 54 and added new Subsec. (e) to specify that
nonlegend drug permits issued by commission are nontransferable.
Sec. 20-625. Nonlegend veterinary drugs. Nothing in sections 20-570 to 20-630,
inclusive, shall be construed to prohibit the sale of veterinary drugs that are nonlegend
drugs by any person who holds a permit to sell nonlegend drugs.
(P.A. 95-264, S. 44; P.A. 99-175, S. 43.)
History: P.A. 99-175 replaced reference to Sec. 20-624 with reference to Sec. 20-630.
Sec. 20-626. Confidentiality of pharmacy records. (a) No pharmacist or pharmacy shall reveal any records or information concerning the nature of pharmaceutical
services rendered to a patient without the oral or written consent of the patient or the
patient's agent. If a patient or a patient's agent gives oral consent to release records or
information, the pharmacist shall promptly record, in writing or in electronic data base
form, the oral consent by listing the patient's name, the name of the patient's agent, if
applicable, the date and the nature of the records or information released.
(b) Notwithstanding subsection (a) of this section, a pharmacist or pharmacy may
provide pharmacy records or information to the following: (1) The patient; (2) the prescribing practitioner or a pharmacist or another prescribing practitioner presently treating the patient when deemed medically appropriate; (3) a person registered or licensed
pursuant to chapter 378 who is acting as an agent for a prescribing practitioner that is
presently treating the patient or a person registered or licensed pursuant to chapter 378
providing care to the patient in a hospital; (4) third party payors who pay claims for
pharmaceutical services rendered to a patient or who have a formal agreement or contract
to audit any records or information in connection with such claims; (5) any governmental
agency with statutory authority to review or obtain such information; (6) any individual,
the state or federal government or any agency thereof or court pursuant to a subpoena;
and (7) any individual, corporation, partnership or other legal entity which has a written
agreement with a pharmacy to access the pharmacy's database provided the information
accessed is limited to data which does not identify specific individuals.
(P.A. 95-85; P.A. 99-175, S. 44.)
History: P.A. 99-175 amended Subsec. (b) to make technical changes.
Subsec. (a):
Statute is intended to protect information concerning the nature of customer's treatment and not pharmacy's billing
practices. 53 CA 129.
Subsec. (b):
Pharmacy required to comply with investigative demand of Commissioner of Consumer Protection. Civil investigative
demand determined to be equivalent of subpoena. 53 CA 129.
Sec. 20-627. Nonresident pharmacy. Definitions. Certificate of registration.
Requirements. (a) As used in sections 20-627 to 20-630, inclusive, "nonresident pharmacy" means any pharmacy located outside this state which ships, mails or delivers, in
any manner, legend devices or legend drugs into this state pursuant to a prescription
order.
(b) A nonresident pharmacy shall be registered with the department, upon approval
of the commission, and shall:
(1) Disclose annually in a report to the commission the location, names and titles
of all principal corporate officers, if applicable, and all pharmacists who are dispensing
drugs or devices to residents of this state. A nonresident pharmacy shall file an additional
report within thirty days after any change of office, corporate officer or pharmacist.
(2) Submit a statement that the nonresident pharmacy complies with all lawful directions and requests for information from the regulatory or licensing agency of the state
in which it is licensed as well as comply with all requests for information made by the
commission pursuant to this section.
(3) Maintain at all times, a valid unexpired license, permit or registration to conduct
such pharmacy in compliance with the laws of the state in which the nonresident pharmacy is located.
(4) Before receiving a certificate of registration from the department, submit a copy
of the most recent inspection report resulting from an inspection conducted by the regulatory or licensing agency of the state in which the nonresident pharmacy is located.
(c) A nonresident pharmacy shall, during its regular hours of operation, but not less
than six days per week, and for a minimum of forty hours per week, provide a toll-free telephone number to facilitate communication between patients in this state and a
pharmacist at such nonresident pharmacy who has access to the patient's records. Such
toll-free telephone number shall be disclosed on a label affixed to each container of
drugs dispensed to patients in this state.
(P.A. 96-127, S. 1; P.A. 99-175, S. 45.)
History: P.A. 99-175 made technical changes, reordered Subsecs., amended Subsec. (a) to delete reference to Sec. 20-184a and deleted former Subsec. (c).
Sec. 20-628. Shipping, mailing or delivering legend devices or drugs. No nonresident pharmacy shall engage in the business of shipping, mailing or delivering legend
devices or legend drugs in this state unless such nonresident pharmacy has been issued
a certificate of registration by the commission and has paid the fee for issuance or renewal
of such certificate of registration required in section 20-601. Applications for a certificate
of registration as a nonresident pharmacy shall be made on a form furnished by the
commission. The commission may require such information as it deems reasonably
necessary to carry out the purpose of this section.
(P.A. 96-127, S. 2; P.A. 99-175, S. 46.)
History: P.A. 99-175 made technical changes, deleted reference to Sec. 20-184a and added provision requiring nonresident pharmacists to pay initial and renewal registration fees as a condition of shipping, mailing or delivering legend devices
or drugs in this state.
Sec. 20-629. Suspension or revocation of certificate. (a) The commission may
deny, revoke or suspend any certificate of registration as a nonresident pharmacy for
failure to comply with any requirement of sections 20-627 to 20-630, inclusive.
(b) The commission may deny, revoke or suspend any certificate of registration as a
nonresident pharmacy for conduct which causes serious bodily or serious psychological
injury to a resident of this state if the commission has referred the matter to the regulatory
or licensing agency in the state in which the nonresident pharmacy is located and such
regulatory or licensing agency fails to (1) initiate an investigation within forty-five days
of referral, (2) complete its investigation within one hundred twenty days of referral,
(3) resolve the referral through formal agreement, settlement or decision within one
hundred eighty days, or (4) initiate disciplinary proceedings when such proceedings are
determined to be necessary in the judgment of the regulatory or licensing agency in the
state in which the nonresident pharmacy is located.
(P.A. 96-127, S. 3; P.A. 99-175, S. 47.)
History: P.A. 99-175 made technical changes.
Sec. 20-630. Advertising. It shall be unlawful for any nonresident pharmacy which
has not been issued a certificate of registration pursuant to section 20-628 to advertise
its services in this state, or for any person who is a resident of this state to advertise the
pharmacy services of a nonresident pharmacy which has not received a certificate of
registration from the commission, with the knowledge that the advertisement will or is
likely to induce members of the public in this state to use the pharmacy to dispense
prescription orders.
(P.A. 96-127, S. 4; P.A. 99-175, S. 48.)
History: P.A. 99-175 made a technical change.
Sec. 20-631. Collaborative drug therapy management agreements between
pharmacist employed by a hospital or nursing home facility and one or more physicians. Regulations. (a)(1) One or more pharmacists licensed under this chapter who
are determined eligible in accordance with subsection (c) of this section, and employed
by a hospital may enter into a written protocol-based collaborative drug therapy management agreement with one or more physicians licensed under chapter 370 to manage the
drug therapy of individual patients receiving inpatient services in a hospital licensed
under chapter 368v, in accordance with subsections (b) to (d), inclusive, of this section
and subject to the approval of the hospital. Each patient's collaborative drug therapy
management shall be governed by a written protocol specific to that patient established
by the treating physician in consultation with the pharmacist.
(2) One or more pharmacists licensed under this chapter who are determined eligible
in accordance with subsection (c) of this section and employed by or under contract
with a nursing home facility, as defined in section 19a-521, may enter into a written
protocol-based collaborative drug therapy management agreement with one or more
physicians licensed under chapter 370 to manage the drug therapy of individual patients
receiving services in a nursing home facility, in accordance with subsections (b) to (d),
inclusive, of this section and subject to the approval of the nursing home facility. Each
patient's collaborative drug therapy management shall be governed by a written protocol
specific to that patient established by the treating physician in consultation with the
pharmacist. Each such protocol shall be reviewed and approved by the active organized
medical staff of the nursing home in accordance with the requirements of section 19-13-D8t(i) of the Public Health Code.
(b) A collaborative drug therapy management agreement may authorize a pharmacist to implement, modify or discontinue a drug therapy that has been prescribed for a
patient, order associated laboratory tests and administer drugs, all in accordance with
a patient-specific written protocol. In instances where drug therapy is discontinued, the
pharmacist shall notify the treating physician of such discontinuance no later than
twenty-four hours from the time of such discontinuance. Each protocol developed, pursuant to the collaborative drug therapy management agreement, shall contain detailed
direction concerning the actions that the pharmacist may perform for that patient. The
protocol shall include, but need not be limited to, (1) the specific drug or drugs to be
managed by the pharmacist, (2) the terms and conditions under which drug therapy may
be implemented, modified or discontinued, (3) the conditions and events upon which
the pharmacist is required to notify the physician, and (4) the laboratory tests that may
be ordered. All activities performed by the pharmacist in conjunction with the protocol
shall be documented in the patient's medical record. The pharmacist shall report at least
every thirty days to the physician regarding the patient's drug therapy management.
The collaborative drug therapy management agreement and protocols shall be available
for inspection by the Departments of Public Health and Consumer Protection. A copy
of the protocol shall be filed in the patient's medical record.
(c) A pharmacist shall be responsible for demonstrating, in accordance with this
subsection, the competence necessary for participation in each drug therapy management agreement into which such pharmacist enters. The pharmacist's competency shall
be determined by the hospital or nursing home facility for which the pharmacist is
employed. A copy of the criteria upon which the hospital or nursing home facility determines competency shall be filed with the Commission of Pharmacy.
(d) The Commissioner of Public Health, in consultation with the Commissioner of
Consumer Protection, may adopt regulations, in accordance with chapter 54, concerning
the minimum content of the collaborative drug therapy management agreement and the
written protocol and as otherwise necessary to carry out the purpose of this section.
(P.A. 02-41, S. 1; P.A. 03-164, S. 1; June 30 Sp. Sess. P.A. 03-6, S. 146(c), (d); P.A. 04-169, S. 17; 04-189, S. 1.)
History: (Revisor's note: In codifying this section the Revisors editorially changed two references in Subsec. (b) from
"pharmacists" to "pharmacist" for consistency); P.A. 03-164 amended Subsec. (a) by designating existing provisions as
Subdiv. (1), making a technical change therein, and adding Subdiv. (2) allowing pharmacists employed by nursing home
facilities to enter into collaborative drug therapy management agreement, and made conforming changes in Subsec. (c);
June 30 Sp. Sess. P.A. 03-6 and P.A. 04-169 replaced Commissioner and Department of Consumer Protection with Commissioner and Department of Agriculture and Consumer Protection, effective July 1, 2004; P.A. 04-189 repealed Sec. 146 of
June 30 Sp. Sess. P.A. 03-6, thereby reversing the merger of the Departments of Agriculture and Consumer Protection,
effective June 1, 2004.
Secs. 20-632 to 20-634. Reserved for future use.
PART IV
PRESCRIPTION ERROR REPORTING
Sec. 20-635. Prescription error reporting. Definitions. Informational signs
and statements. Regulations. Nondisclosure of records. (a) As used in this section:
(1) "Dispensing" means those acts of processing a drug for delivery or for administration for a patient pursuant to a prescription consisting of: (A) Comparing the directions
on the label with the directions on the prescription to determine accuracy; (B) the selection of the drug from stock to fill the prescription; (C) the counting, measuring, compounding or preparation of the drug; (D) the placing of the drug in the proper container;
(E) the affixing of the label to the container; and (F) the addition to a written prescription
of any required notations;
(2) "Drug" means (A) an article recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States or official National
Formulary, or any supplement to any of them, (B) an article intended for use in the
diagnosis, cure, mitigation, treatment or prevention of disease in humans, (C) an article,
other than food, intended to affect the structure or any function of the body of humans;
(3) "Pharmacy" means a place of business where drugs may be sold at retail and
for which a pharmacy license has been issued to an applicant under the provisions of
section 20-594. For the purposes of this section, "pharmacy" shall include any areas of an
institutional pharmacy where prescription drugs are dispensed to outpatients, employees
and retirees;
(4) "Prescribing practitioner" means an individual licensed by the state of Connecticut, any other state of the United States, the District of Columbia, the Commonwealth
of Puerto Rico or any territory or insular possession subject to the jurisdiction of the
United States who is authorized to issue a prescription within the scope of the individual's practice;
(5) "Prescription" means a lawful order of a prescribing practitioner transmitted
either orally, in writing or by electronic means for a drug for a specific patient; and
(6) "Prescription error" means an act or omission of clinical significance relating
to the dispensing of a drug that results in or may reasonably be expected to result in
injury to or death of a patient.
(b) Each pharmacy shall display a sign concerning the reporting of prescription
errors in a conspicuous location visible to consumers of prescription drugs. The sign
shall measure a minimum of eight inches in height and ten inches in length and the
lettering shall be in a size and style that allows such sign to be read without difficulty
by consumers standing at the pharmacy prescription department distribution counter.
The sign shall bear the following statement: "If you have a concern that an error may
have occurred in the dispensing of your prescription you may contact the Department
of Consumer Protection, Drug Control Division, by calling (Department of Consumer
Protection telephone number authorized pursuant to section 21a-2 of the general
statutes)".
(c) Each pharmacy that dispenses a prescription to a consumer shall include the
following printed statement on the receipt or in the bag or other similar packaging in
which the prescription is contained: "If you have a concern that an error may have
occurred in the dispensing of your prescription you may contact the Department of
Consumer Protection, Drug Control Division, by calling (Department of Consumer Protection telephone number authorized pursuant to section 21a-2 of the general statutes)".
The statement shall be printed in a size and style that allows such statement to be read
without difficulty by consumers.
(d) The Commissioner of Consumer Protection shall adopt regulations, with the
advice and assistance of the Commission of Pharmacy, in accordance with chapter 54,
concerning the implementation of a quality assurance program designed to detect, identify and prevent prescription errors in pharmacies. Such regulations shall require that
each pharmacy implement a quality assurance program that describes in writing policies
and procedures to be maintained in such pharmacy. Such policies and procedures shall
include directions for communicating the details of a prescription error to the prescribing
practitioner and to the patient, the patient's caregiver or appropriate family member
if the patient is deceased or is unable to fully comprehend the communication. Such
communication shall describe methods of correcting the prescription error or reducing
the negative impact of the error on the patient. Such regulations shall require that records
of all reported prescription errors shall be maintained in a manner ready for inspection
for a minimum period of three years and that such records shall be made available for
inspection by the Commissioner of Consumer Protection within forty-eight hours in
any case where the commissioner is investigating a report of a prescription error.
(e) Records collected or maintained pursuant to this section shall not be required
to be disclosed pursuant to subsection (a) of section 1-210 for a period of six months
from the date such records were created pursuant to subsections (c) and (d) of this section
and shall not be subject to subpoena or discovery or introduced into evidence in any
judicial proceeding except as otherwise specifically provided by law.
(P.A. 02-48, S. 1; P.A. 03-164, S. 2; June 30 Sp. Sess. P.A. 03-6, S. 146(c), (d); P.A. 04-169, S. 17; 04-189, S. 1.)
History: P.A. 03-164 added Subsec. (e) re disclosure of records; June 30 Sp. Sess. P.A. 03-6 and P.A. 04-169 replaced
Commissioner and Department of Consumer Protection with Commissioner and Department of Agriculture and Consumer
Protection, effective July 1, 2004; P.A. 04-189 repealed Sec. 146 of June 30 Sp. Sess. P.A. 03-6, thereby reversing the
merger of the Departments of Agriculture and Consumer Protection, effective June 1, 2004.